Louisiana State Employees Retirement System Supernus Pharmaceuticals, Inc. Transaction History

Louisiana State Employees Retirement System

  • $5.33 Billion
  • Q3 2024

A detailed history of Louisiana State Employees Retirement System transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Louisiana State Employees Retirement System holds 26,600 shares of SUPN stock, worth $960,791. This represents 0.02% of its overall portfolio holdings.

Number of Shares
26,600
Previous 27,700 3.97%
Holding current value
$960,791
Previous $740,000 12.03%
% of portfolio
0.02%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024
SELL
$25.77 - $35.16 $28,347 - $38,675
-1,100 Reduced 3.97%
26,600 $829,000
Q2 2024

Jul 24, 2024
BUY
$25.99 - $33.85 $15,593 - $20,310
600 Added 2.21%
27,700 $740,000
Q1 2024

Apr 23, 2024
SELL
$27.11 - $35.17 $5,422 - $7,034
-200 Reduced 0.73%
27,100 $924,000
Q4 2023

Jan 29, 2024
SELL
$22.72 - $29.68 $11,360 - $14,840
-500 Reduced 1.8%
27,300 $790,000
Q3 2023

Oct 17, 2023
SELL
$27.57 - $32.91 $22,056 - $26,327
-800 Reduced 2.8%
27,800 $766,000
Q2 2023

Jul 18, 2023
BUY
$29.91 - $38.73 $101,694 - $131,682
3,400 Added 13.49%
28,600 $859,000
Q1 2023

Apr 19, 2023
SELL
$34.93 - $42.03 $17,465 - $21,015
-500 Reduced 1.95%
25,200 $912,000
Q4 2022

Jan 24, 2023
BUY
$31.09 - $37.88 $3,109 - $3,788
100 Added 0.39%
25,700 $917,000
Q3 2022

Oct 19, 2022
SELL
$28.79 - $35.41 $5,758 - $7,081
-200 Reduced 0.78%
25,600 $867,000
Q2 2022

Jul 20, 2022
SELL
$25.33 - $34.25 $2,533 - $3,425
-100 Reduced 0.39%
25,800 $773,000
Q1 2022

Apr 22, 2022
BUY
$28.51 - $32.9 $5,702 - $6,580
200 Added 0.78%
25,900 $768,000
Q4 2021

Jan 14, 2022
BUY
$26.37 - $34.22 $2,637 - $3,422
100 Added 0.39%
25,700 $749,000
Q3 2021

Oct 12, 2021
BUY
$23.54 - $31.39 $40,018 - $53,363
1,700 Added 7.11%
25,600 $683,000
Q2 2021

Jul 16, 2021
SELL
$26.72 - $33.19 $2,672 - $3,319
-100 Reduced 0.42%
23,900 $736,000
Q1 2021

Apr 14, 2021
SELL
$24.15 - $31.45 $7,245 - $9,435
-300 Reduced 1.23%
24,000 $628,000
Q4 2020

Jan 11, 2021
SELL
$17.7 - $25.81 $1,770 - $2,581
-100 Reduced 0.41%
24,300 $611,000
Q3 2020

Oct 19, 2020
BUY
$20.2 - $25.05 $203,818 - $252,754
10,090 Added 70.51%
24,400 $508,000
Q2 2020

Jul 13, 2020
SELL
$17.09 - $24.89 $3,418 - $4,978
-200 Reduced 1.38%
14,310 $340,000
Q1 2020

Apr 13, 2020
SELL
$14.45 - $24.69 $50,286 - $85,921
-3,480 Reduced 19.34%
14,510 $261,000
Q4 2019

Jan 17, 2020
SELL
$19.93 - $29.13 $28,101 - $41,073
-1,410 Reduced 7.27%
17,990 $427,000
Q3 2019

Oct 24, 2019
SELL
$25.47 - $33.37 $2,547 - $3,336
-100 Reduced 0.51%
19,400 $533,000
Q2 2019

Jul 15, 2019
SELL
$29.96 - $38.87 $2,996 - $3,886
-100 Reduced 0.51%
19,500 $622,000
Q1 2019

Apr 15, 2019
SELL
$32.77 - $41.99 $98 - $125
-3 Reduced 0.02%
19,600 $687,000
Q4 2018

Jan 14, 2019
SELL
$30.84 - $49.51 $104,763 - $168,185
-3,397 Reduced 14.77%
19,603 $651,000
Q3 2018

Oct 16, 2018
SELL
$42.7 - $56.55 $8,540 - $11,310
-200 Reduced 0.86%
23,000 $1.16 Million
Q2 2018

Jul 18, 2018
BUY
$44.1 - $59.85 $13,230 - $17,955
300 Added 1.31%
23,200 $1.39 Million
Q1 2018

Apr 18, 2018
BUY
$37.15 - $46.9 $29,720 - $37,520
800 Added 3.62%
22,900 $1.05 Million
Q4 2017

Jan 16, 2018
BUY
$36.4 - $42.6 $58,240 - $68,160
1,600 Added 7.8%
22,100 $881,000
Q3 2017

Oct 16, 2017
BUY
$36.75 - $49.65 $753,375 - $1.02 Million
20,500
20,500 $820,000

Others Institutions Holding SUPN

# of Institutions
282
Shares Held
60.9M
Call Options Held
27.7K
Put Options Held
11.3K
View Full List

About SUPERNUS PHARMACEUTICALS, INC.

SUPN Quotes by TradingView
  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.93B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Louisiana State Employees Retirement System Portfolio

Follow Louisiana State Employees Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Louisiana State Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on Louisiana State Employees Retirement System with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email